New drug for type 2 diabetes is no better than older, cheaper treatments, says institute

BMJ 2012; 345 doi: http://dx.doi.org/10.1136/bmj.e8593 (Published 19 December 2012)
Cite this as: BMJ 2012;345:e8593

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Ned Stafford
  1. 1Hamburg

The agency responsible for evaluating the effectiveness of drugs in Germany has for a second time concluded that linagliptin, a new drug used to treat type 2 diabetes, offers no added benefit over older, less expensive treatments already on the market.1

The agency, the Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Healthcare), widely known as IQWIG, is evaluating linagliptin as part of a complex process to determine the reimbursement price paid by Germany’s public health insurance system to drug companies to cover the cost of treatment with the drug.

Linagliptin was approved …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL